Market revenue in 2023 | USD 30.6 million |
Market revenue in 2030 | USD 75.6 million |
Growth rate | 13.8% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.13% in 2023. Horizon Databook has segmented the South Korea head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The pharmaceutical market in South Korea is a growing and competitive industry. It is one of the largest markets in Asia and has been witnessing steady growth over the years. The country has a well-developed healthcare system and strongly emphasizes R&D, making it a lucrative market for pharmaceutical companies.
Increasing R&D investments by key pharmaceutical companies in South Korea are expected to create a lucrative environment for market growth. For instance, in October 2022, AstraZeneca announced that it will spend USD 630.0 million on R&D in South Korea over the next 5 years to improve access to healthcare. The rising prevalence of head and neck cancer also drives the market growth.
The lip & oral cavity and larynx cancer are the most common types of head and neck cancer in South Korea. Furthermore, key players have constantly been focusing on the launch of products and geographic expansion to diversify and expand their product portfolios.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into South Korea head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account